Yixintang Pharmaceutical (SZ:002727) Zheng Quan Zhi Xing·2025-07-14 09:10Core Viewpoint - The company has approved the use of up to RMB 325 million of temporarily idle funds from its 2018 convertible bond issuance for cash management purposes, which includes investments in low-risk financial products [1] Group 1: Cash Management Overview - The company held its annual shareholders' meeting on May 21, 2025, where it approved the cash management proposal [1] - The approved cash management amount is capped at RMB 325 million, which can be used for various financial products such as fixed-income investments, large deposits, and time deposits [1] - The company has signed a contract with Shanghai Pudong Development Bank for a structured deposit product, investing RMB 75 million with a minimum guaranteed return of 0.70% and a floating return of up to 1.20% [2] Group 2: Investment Risk Analysis and Control Measures - The cash management products are categorized as low-risk investments, but they are still subject to market fluctuations due to macroeconomic factors [3] - The company will monitor economic conditions and adjust its investment strategy accordingly to manage risks [3] - Internal audits and oversight by independent directors and the sponsor institution will be conducted to ensure the safety of the funds [3] Group 3: Impact on Company Performance - The cash management initiative is expected to enhance the company's overall performance and provide better returns for shareholders while ensuring the safety of the raised funds [4]